title: [Percutaneous ethanol injection in combination with euthyrox suppressive therapy in the treatment of benign nodular goiter].
abstract: This study was designed to clarify the efficacy of combination of thyroid hormone (euthyrox) therapy and percutaneous ethanol injection (PEI) in benign nodular thyroid diseases. 55 patients with benign nodular goiter after the first PEI session during the whole study period (from 3 till 12 months after PEI) daily received euthyrox in a dosage - 50 mkg. 48 women and 7 men with thyroid nodules of the various sizes, structures and echogenecity have been included in the study group. The control group consisted of 32 patients: 29 women and 3 men in the same age range as in the study group. In both groups PEI procedure was performed but in the control group no thyroid hormone was added. In patients who were receiving 50 mkg daily after 3 months of PEI progressive reduction of the nodule sizes was registered, the volume of a thyroid gland has decreased and approached to normal parameters (15,79+/-1,21 ml), and in 6-2 months the normal volume of the thyroid gland was registered. Thus, combination of thyroid hormone therapy and percutaneous ethanol injection (PEI) in treatment of patients with benign nodular goiter normalizes the size of a thyroid gland. Euthyrox is the additional factor causing reduction of thyroid nodules and constraining occurrence of new nodules in a thyroid gland.
authors.forename: I A
authors.initials: IA
authors.lastname: Meskhi
authors.forename: E N
authors.initials: EN
authors.lastname: Sikharulidze
authors.forename: K V
authors.initials: KV
authors.lastname: Natmeladze
mesh_terms: D004359:Drug Therapy, Combination; D000431:Ethanol / Q000627:therapeutic use*; D005260:Female; D006044:Goiter, Nodular / Q000188:drug therapy*; D006801:Humans; D007279:Injections, Subcutaneous; D008297:Male; D013974:Thyroxine / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000431:Ethanol; D013974:Thyroxine